Abstract: INFO11-SA
Cure Glomerulonephropathy Network (CureGN)
Session Information
- Informational Posters - III
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Nestor, Jordan Gabriela, Columbia University, New York, New York, United States
- D'Alessandri-Silva, Cynthia J., Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Mansfield, Sarah, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
- Helmuth, Margaret, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
- Wang, Chia- Shi, Emory University, Atlanta, Georgia, United States
- Ahn, Wooin, Columbia University, New York, New York, United States
- Zee, Jarcy, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
- Glenn, Dorey A., University of North Carolina, Chapel Hill, North Carolina, United States
Background
CureGN is a multi-center, prospective observational study of glomerular disease funded by the NIH-NIDDK. To date, CureGN has enrolled 2322 of 2400 children and adults with biopsy-proven minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy/vasculitis (IgAN/IgAV) from 70 sites in the USA, Canada, Italy, and Poland.
Methods
Patients with a diagnostic kidney biopsy within 5 years are eligible to participate. Exclusion criteria include end-stage kidney disease (ESKD) at enrollment and glomerular disease attributed to a secondary cause. Visits are conducted 3 times/year, with one mandatory annual in-person visit. In addition to clinical and patient-reported outcomes, biospecimens are collected, as well as outcomes of ESKD, death, and non-renal complications (e.g., infection, malignancy, cardiovascular and thromboembolic events). CureGN supports clinical and translational research by combining detailed clinical data with a biorepository of DNA, RNA, blood, and urine specimens as well as a Digital Pathology Repository (DPR) of biopsy images to provide a shared tool for investigators.
Results
Enrollment began 12/2014. The consortium has maintained a participant retention rate of 84% over a median follow-up of 2.1 years. Participant demographic and outcome data as of March 2019 are shown in Table 1. To date, 896 (39%) cases in the DPR have been scanned and digitally archived and are being scored.
Conclusion
The study objectives support a variety of approaches to identify mechanistically distinct subgroups, define accurate biomarkers of disease activity, delineate disease-specific treatment targets and inform future therapeutic trials to advance the diagnosis, care, and outcomes of glomerular disease. A total of 4 publications, presenting baseline descrriptive data, and 13 ancillaries studies have emerged from this initiative.
Funding
- NIDDK Support